Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
HANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals ("Chance"), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation...
-
HANGZHOU, China, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation...
-
HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing...
-
HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing...
-
中国杭州, Feb. 09, 2021 (GLOBE NEWSWIRE) -- 杭州畅溪制药（以下简称“畅溪”）与Aerami Therapeutics（以下简称“Aerami”）有限公司联合宣布其共同签署了⼀项独家许可及产品开发协议，畅溪将从Aerami获得其肺动脉高压候选药物AER-901在大中华地区（中国境内及港澳台）独家开发和商业化权利。 ...
-
HANGZHOU, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing and commercializing...